-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women’s Hospital and an instructor of neurology at Harvard Medical ...
-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...
New Brunswick, N.J. (October 28, 2021) – Combining electroencephalogram (EEG) data with clinical observations can help doctors to better determine whether generalized epilepsy patients will respond to ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Valproate (Depakene) emerged as the best first-line choice for ...
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...
People with generalized epilepsy who have seizures arising from both sides of the brain simultaneously, have a higher risk of obstructive sleep apnea (OSA) compared to patients who have focal epilepsy ...
NASHVILLE, Tennessee ―The retention rate for the antiseizure drug perampanel (Eisai Co, Ltd) is more than 70% for adult patients with epilepsy, new research shows. In early results from the PERPRISE ...
Please provide your email address to receive an email when new articles are posted on . Among 2,214 persons with epilepsy, 7.5% had MDD, and 4% had generalized anxiety disorder. Those on valproic acid ...
Verywell Health on MSN

What are the main causes of epilepsy?

Medically reviewed by Diana Apetauerova, MD Key Takeaways Epilepsy is often linked to genetic factors, brain injuries, ...
MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...